The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 7 of the 12 sources its claims cite were checked for support.
SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab
Open accessAbstract
Multicenter retrospective analysis combining SUVmax with inflammatory markers into a prognostic index for metastatic NSCLC.
Overview
CoChat Summary
TL;DR
This multicenter retrospective study of 187 metastatic NSCLC patients treated with nivolumab found that a composite score, SUVmax-IPI, was independently associated with overall survival but not progression-free survival. The score outperformed SUVmax alone and showed better fit than IPI alone, but its discrimination was modest and the cutoff needs external validation.
Key findings
- In 187 patients, the optimal SUVmax-IPI cutoff was 241.9; 65.2% of patients were at or below this threshold and 34.8% were above it.
- Patients with SUVmax-IPI > 241.9 had shorter overall survival than those with SUVmax-IPI ≤ 241.9: median OS 15 vs 35 months (log-rank p = 0.002); 1-year OS 58.6% vs 78.3% and 2-year OS 29.8% vs 54.5%.
- SUVmax-IPI was not significantly associated with progression-free survival: median PFS 8.0 vs 15.0 months (log-rank p = 0.175).
- In multivariable analysis, SUVmax-IPI > 241.9 remained an independent predictor of OS (HR 2.50; 95% CI 1.39–4.49; p = 0.002), while the model’s discrimination was modest (OS C-index 0.583; PFS C-index 0.525).
- Compared with its components, SUVmax alone was not significantly associated with OS (HR 1.06; p = 0.805), while SUVmax-IPI was significant in both univariate and multivariate analyses (HR 1.96; p = 0.002; multivariate HR 1.97; p = 0.032).
Methods
- Multicenter retrospective study across 5 tertiary hospitals in Turkey, including 187 consecutive patients with histologically confirmed metastatic NSCLC treated with nivolumab between May 2019 and December 2024; eligibility required age ≥18, ≥3 months of nivolumab, and available post-treatment FDG-PET and laboratory data.
- SUVmax was taken from pretreatment FDG-PET, IPI was calculated as (CRP × NLR)/albumin, and SUVmax-IPI was defined as SUVmax × IPI; an ROC analysis with Youden’s index set the cutoff at 241.9.
- Survival was analyzed using Kaplan–Meier/log-rank testing and univariable/multivariable Cox regression; the paper also reports time-dependent AUC, Harrell’s C-index, calibration, landmark analyses at 2 and 3 months, decision curve analysis, and comparisons against LIPI, NLR, PLR, and SII.
Limitations
- The authors state that the study is retrospective, the cutoff was derived within the same cohort and may be overfit, and external validation is required before clinical use.
- The authors state that requiring at least 3 months of nivolumab limits generalizability to patients who discontinue earlier.
- Evident from the text: discrimination was modest (e.g., OS AUC 0.368 at 12 months and 0.337 at 24 months; PFS AUC 0.443 and 0.395), which suggests limited predictive performance despite statistical significance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
6 Valid · 0 Not valid · 4 Not checked · 30 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While programmed death ligand 1 (PD-L1) expression and tumor mutational burden are established predictive markers, their clinical utility is limited by spatial heterogeneity, assay variability, and dynamic changes during therapy [4].”
§ SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab > 1. Introduction
What the sources say
- Partly supportedcites [4] Havel, 2019, The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy, Nat. Rev. Cancer sourceExperimental — accuracy not yet measured
The ‘PDL1 expression’ section identifies different detection assays, temporal changes and intratumoural heterogeneity as potential reasons for inconsistent PD-L1 biomarker findings. The ‘Tumour antigens and mutation burden’ section says pre-therapy TMB has limited predictive accuracy and that on-therapy TMB changes can be informative. The cited passages do not establish that spatial heterogeneity and assay variability also limit TMB’s clinical utility, as the sentence implies. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI ≤ 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175).”
§ SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab > Abstract > Abstract Background/Objectives: Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need. To address this gap, we developed the SUVmax-IPI, a novel prognostic index combining maximum standardized uptake value (SUVmax) from 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) with systemic inflammatory markers. This study aimed to evaluate the prognostic value of SUVmax-IPI in patients with NSCLC receiving nivolumab therapy. Methods: This multicenter retrospective analysis included 187 patients with metastatic NSCLC receiving nivolumab across 5 tertiary institutions. The SUVmax-IPI incorporated pretreatment SUVmax and laboratory-based inflammatory prognostic index (IPI) parameters. Survival outcomes were evaluated using Kaplan–Meier analysis with log-rank testing and multivariate cox regression. Results: Receiver operating characteristic (ROC) analysis established an optimal SUVmax-IPI cut-off of 241.9. Patients with SUVmax-IPI ≤ 241.9 had significantly better survival outcomes: median overall survival (OS) was 35 versus 15 months (p = 0.002). For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI ≤ 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175). Multivariate analysis confirmed SUVmax-IPI as an independent predictor of survival (p = 0.002). Conclusions: The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes.
plainn = 187- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the IPI demonstrated a significant association with survival outcomes (HR = 1.66; 95% CI, 1.06–2.60; p = 0.028).”
§ SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab > 3. Results > 3.6. Comparative Performance of SUVmax-IPI Against IPI and SUVmax Alone
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ROC curve analysis established 241.9 as the optimal SUVmax-IPI threshold (area under the curve, 0.57).”
§ SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab > 3. Results > 3.1. Patient Characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In univariate Cox regression analysis, SUVmax alone was not significantly associated with overall survival (HR = 1.06, p = 0.805).”
§ SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab > 3. Results > 3.6. Comparative Performance of SUVmax-IPI Against IPI and SUVmax Alone
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
8 more claims
Create a free account to see all 40 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 16
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“Metabolic dysregulation is a central feature of oncogenesis, characterized by a pronounced shift toward aerobic glycolysis (Warburg effect) [5].”
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“The advent of immune checkpoint inhibitors, particularly nivolumab, has redefined therapeutic paradigms, demonstrating superior survival outcomes compared to chemotherapy in both squamous and non-squamous NSCLC subtypes [2,3].”
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“The advent of immune checkpoint inhibitors, particularly nivolumab, has redefined therapeutic paradigms, demonstrating superior survival outcomes compared to chemotherapy in both squamous and non-squamous NSCLC subtypes [2,3].”
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 2×
“While programmed death ligand 1 (PD-L1) expression and tumor mutational burden are established predictive markers, their clinical utility is limited by spatial heterogeneity, assay variability, and dynamic changes during therapy [4].”
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913 · cited 2×
“Mezquita et al. reported that patients who had poor LIPI scores showed significantly shorter PFS and OS after receiving immune checkpoint inhibitors [9].”
Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364 · cited 2×
“Similarly, pretreatment systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were independently associated with reduced progression-free survival and overall survival in those receiving nivolumab [10].”
Cerfolio, R. J., Bryant, A. S., Ohja, B., & Bartolucci, A. A. (2005) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.11.007 · Cited by 317 · cited 1×
“Prior research has suggested that SUVmax of primary tumors may serve as a prognostic indicator in patients with NSCLC [12,13].”
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3806-1 · Cited by 195 · cited 2×
“Recent studies have demonstrated that metabolic parameters such as SUVmax, metabolic tumor volume, and total lesion glycolysis can predict responses to immune checkpoint inhibitors, with elevated baseline SUVmax values associated with less favorable outcomes [7,8].”
Machtay, M., Duan, F., Siegel, B. A., Snyder, B. S., Gorelick, J. J., Reddin, J. S., Munden, R., Johnson, D. W., Wilf, L. H., DeNittis, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5947 · Cited by 175
Research works printed but not linked: 2
- Tomita, 2018, Inflammatory Prognostic Index in Resected NSCLC, Asian Pac. J. Cancer Prev., 19, 2867
- Jin, 2016, Prognostic Value of the Standardized Uptake Value Maximum Change Calculated by Dual-Time-Point (18F)-Fluorodeoxyglucose PET Imaging in Patients with Advanced NSCLC, OncoTargets Ther., 9, 2993
Cited by
Prognostic value of the CHAM score in non-small cell lung cancer patients treated with nivolumab
Ağaoğlu, A. B., Ekinci, F., Şahbazlar, M., & Erdoğan, A. P. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04421-6 · Cited by 1
Self-citationGüzel, E. Z., Ekinci, F., Erdoğan, A. P., & Şahbazlar, M. (2025) · Research Square · doi:10.21203/rs.3.rs-8254045/v1
Self-citation
Metadata
- Authors
- Kolkıran, N., Erdoğan, A. P., Şahbazlar, M., Taş, S., Gököz Doğu, G., Canaslan, K., Ünek, İ. T., Demirkıran, Ö., Demir, B., Teküstün, G. N., Tanrıverdi, Ö., & Ekinci, F.
- Affiliations
- Manisa Celal Bayar University (TR)
- Pamukkale University (TR)
- Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey
- Dokuz Eylül University (TR)
- Adnan Menderes University (TR)
- Muğla University (TR)
- Corresponding author
- Kolkıran, Nagihan
- ORCID
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2025-10-09
- Volume
- 32
- Issue
- 10
- Pages
- 566
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- PMC
- PMC12564384
- OpenAlex
- W4414989296
- Cited by
- 2
- References
- 19
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Manisa Celal Bayar Üniversitesi
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- metastatic non-small cell lung cancer, nivolumab, prognostic score, SUVmax, FDG-PET, systemic inflammatory markers, overall survival, progression-free survival, immune checkpoint therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Retrospective Studies, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. https://app.cochat.ai/papers/10.3390/curroncol32100566
- The paper
- Kolkıran, N., Erdoğan, A. P., Şahbazlar, M., Taş, S., Gököz Doğu, G., Canaslan, K., Ünek, İ. T., Demirkıran, Ö., Demir, B., Teküstün, G. N., Tanrıverdi, Ö., & Ekinci, F. (2025). SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. Current Oncology. https://doi.org/10.3390/curroncol32100566
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.